The aim of the study was to evaluate peripheral blood progenitor cell mobilization by disease-specific chemotherapy in heavily pretreated patients with germ cell tumor (GCT), scheduled for high-dose chemotherapy. Thirty-four consecutive patients, 29 males and five females, with advanced GCT referred to our department for high-dose chemotherapy were evaluated retrospectively. Sixteen patients were mobilized by vinblastine 0.11 mg/kg on days 1 and 2, ifosfamide 1200 mg/m 2 days 1-5 and cisplatin 20 mg/m 2 days 1-5 (VeIP). In 10 patients, etoposide 75 mg/m 2 days 1-5 was used instead of vinblastine (VIP), while in eight patients the mobilization was attempted by administering 7 g/m 2 of cyclophosphamide. The choice of either etoposide or vinblastine was predicated upon which of these two drugs was associated with best results during premobilization chemotherapy. Cyclophosphamide was selected in patients refractory to previous cisplatin-based salvage chemotherapy. Twenty-five out of 34 patients underwent a successful PBPC collection. In 17 of them one leukapheresis procedure was sufficient to collect the target number of CD34 ؉ cells, while in eight patients a double procedure was necessary. Altogether 33 aphereses were performed in 25 patients. In nine patients leukapheresis was not attempted. This was due to the fact that the chemotherapy failed to mobilize the target number of CD34 ؉ cells in eight of them, treated with the VeIP mobilizing regimen, while one patient treated with high-dose cyclophosphamide rapidly progressed during therapy and for this reason leukapheresis was not undertaken. In conclusion, in heavily pretreated patients with GCT, PBPC mobilization is feasible by a further course of salvage chemotherapy. The choice of either etoposide (VIP) or vinblastine (VeIP) can be predicated upon which of these two drugs was associated with best results during premobilization chemotherapy. In our hands, VeIP seems to be less satisfactory as mobilizing treatment than VIP, possibly due to a superior number of premobilization courses of chemotherapy in some patients. Moreover, high-dose cycloCorrespondence: Dr C Dazzi, Dipartimento di Oncologia, Ospedale Santa Maria delle Croci, Viale Randi 5, 48100 Ravenna, Italy Received 9 September 1998; accepted 5 November 1998 phosphamide remains a good alternative for mobilizing patients refractory to salvage chemotherapy.
Testicular cancer has recently become a model for a curable tumor. Nowadays about 70-80% of patients with disseminated germ cell tumors (GCT) can be cured with combined modality treatment including surgery, radiotherapy and cisplatin-based chemotherapy. 1, 2 Nevertheless there is a fraction of patients who do not respond completely or relapse. For these patients the chance of cure is considerably less favorable; the possibility of obtaining a complete remission (CR) with a conventional salvage treatment is about 50%, but only 15% to 27% of them remain in durable complete remission. 1, 2 The peculiar chemosensitivity of GCT, unusual occurrence of bone marrow metastases and younger median age have induced several investigators to test the activity of high dose-chemotherapy with hematopoietic stem cell rescue. Overall, the results in heavily pretreated patients with refractory and relapsing GCT showed that a proportion of patients can be cured: 15 to 35% of them remain alive and disease-free with long-term followup. [3] [4] [5] [6] The use of high-dose chemotherapy with autologous stem cell rescue as initial salvage therapy has been relatively less well investigated with conflicting results. 7, 8 Recent retrospective clinical studies and one randomized trial have clearly demonstrated that recovery of hematopoiesis occurs significantly faster after peripheral blood progenitor cells (PBPC) than autologous bone marrow reinfusion. [9] [10] [11] Furthermore, patients rescued with PBPC had a shorter hospital stay, fewer febrile days and lower antibiotic use, red cell and platelet transfusions compared to those receiving ABMT. [9] [10] [11] The increased safety of PBPC is also reflected in a low procedure-related mortality. In Europe PBPC have almost entirely replaced ABMT hematopoietic support. 12 Unfortunately, mobilization attempts are sometimes unsuccessful, due either to disease-related impaired hematopoiesis, as in multiple myeloma, 13 or to chemotherapy-related exhaustion of the bone marrow stem cell pool.
14 In GCT patients, attempts to collect PBPC are most often performed after six or more cisplatin-containing chemotherapy courses. Addition of a further mobilizing chemotherapy course may fail to enhance the amount of circulating PBPC. The aim of this study was to evaluate peripheral blood progenitor cell mobilization by disease-specific chemotherapy in heavily pretreated patients with GCT, scheduled for high-dose chemotherapy.
Patients and methods

Patients
Thirty-four consecutive patients, 29 males and five females, with advanced GCT referred to our department for PBPC mobilization and collection, were retrospectively evaluated.
PBPC mobilization
Sixteen patients were mobilized by vinblastine 0.11 mg/kg on days 1 and 2, ifosfamide 1200 mg/m 2 days 1-5 and cisplatin 20 mg/m 2 days 1-5 (VeIP). In 10 patients etoposide 75 mg/m 2 days 1-5 was used instead of vinblastine (VIP), while in eight patients the mobilization was attempted by administering 7 g/m 2 of cyclophosphamide. Cyclophosphamide was usually preferred in patients refractory to previous cisplatin-based salvage chemotherapy. Hematopoietic growth factor administration was started 24 h after the end of chemotherapy at 5 g/kg/day subcutaneously and continued until completion of PBPC harvest.
PBPC collection
Blood samples were obtained once a day starting on day 7 after the first day of chemotherapy and when the WBC count clearly began to rise, CD34 ϩ cells were detected using the 8G12 antibody. The decision to start leukapheresis was taken when numbers of circulating CD34 ϩ cells were у20/l of peripheral blood. The number of CD34 ϩ cells considered as the target for each high-dose chemotherapy was у2 ϫ 10 6 /kg/bw, as accepted by the majority of investigators. 12 The PBPC collection procedures were performed using the MNC program of Spectra COBE BCT, Apheresis System (Cobe, Lakewood, Co, USA). A total blood volume of 6-9 l per apheresis was processed through double lumen apheresis catheters or by venous puncture for 3-4 h at a flow rate of 45-50 ml/min. PBPC concentrates were cryopreserved with a final dimethyl sulfoxide concentration of 10%. Suspensions were frozen in cryopreservation bags and stored in liquid nitrogen. Granulocytemacrophage colony-forming units (CFU-GM) were assayed in a semisolid medium, and after 14 days of incubation, all colonies with more than 40 cells were counted under an inverted microscope.
Results
Patient characteristics
All patients had metastatic GCT refractory, at least, to a first line of cisplatin-containing chemotherapy or relapsed after standard first and/or second-line regimens. The characteristics of the patients are listed in Table 1 , and distributed in three groups on the basis of the chemotherapy regimen used to mobilize PBPC. 
PBPC mobilization
The mobilization regimen was determined by disease response to premobilization chemotherapy. Fourteen patients responding to VeIP continued with the same therapy for mobilization. Ten patients were mobilized with VIP because they were responsive to the same premobilization chemotherapy, whereas two patients were refractory to VIP and mobilized with VeIP. Cyclophosphamide was usually preferred in patients refractory to previous cisplatin-based salvage chemotherapy. The majority of patients (27/34) received filgrastim starting 24 h from the end of chemotherapy, while lenograstim was administered in three patients and molgramostim in four, according to protocols in use at our institution at the time of admission.
Toxicity of mobilizing regimen
Sixty per cent of patients experienced vomiting grade 3 according to Common Toxicity Criteria. 15 Neurological and renal toxicities were usually mild. Hematological toxicity was worse for patients treated either with high-dose cyclophosphamide or VeIP regimen (Table 2) . Eleven patients needed two units of red blood cells. Two patients received Table 3 for details).
Patients who did not mobilize
In nine patients collection was not attempted, due to failure of mobilization of the target number of CD34 ϩ cells in eight of them, treated with the VeIP mobilizing regimen, whereas one patient treated with high-dose cyclophosphamide, rapidly progressed during therapy. The peripheral blood CD34 ϩ cell concentration varied between 0.1 and 0.4 ϫ 10 6 /kg. Four out of nine patients who did not mobilize received three regimens of cisplatinum-based chemotherapy before mobilization while the other five received only two regimens of chemotherapy like most of the patients (24/25) who underwent a successful mobilization and collection.
Discussion
The present study focused on the feasibility of mobilization and collection of PBPC in heavily pretreated patients with metastatic GCT, by the use of disease-specific chemotherapy or high-dose cyclophosphamide. Mobilization of PBPC is usually performed by the administration of highdose cyclophosphamide and growth factors in various malignant diseases. The possibility of using disease-specific chemotherapy has been demonstrated recently by Schwella et al 16 in nine patients affected by soft tissue sarcomas. In our series, the choice of mobilization regimen was determined by disease response to premobilization chemo- Table 3 Hematological values on the day of leukapheresis. Circulating and collected CD34 ϩ cells
Mobilizing regimen VeIP (8 patients) VIP (10 patients) CTX (7 patients)
Median WBC ϫ10 Vinblastine is a vinca alkaloid tested extensively in the past three decades, whose primary toxicity is leukopenia. The peripheral white count reaches a nadir at day 6 to 7 and is rapidly reversible. Therefore, the major site of action of vinblastine, appears to be on committed myeloid progenitor cells. 17 Although busulfan, BCNU and cytarabine have already been shown to act selectively against CFU-GM and CFU-S, the same has not been found for vinblastine. 18, 19 If we look at hematological toxicity of mobilizing regimens (Table 2 ), VeIP appears to be more toxic than VIP regarding platelets and white cells. However, data in the literature do not seem to confirm our impression. [20] [21] [22] Hornung and Longo 14 have elegantly demonstrated in mice that repeated treatments with myelosuppressive drugs, followed by stimulation with either G-CSF or GM-CSF, induce damage to the host stem cell compartment; therefore the CFU-S activity and longterm marrow repopulating ability of the marrow from mice receiving repeated courses of cyclophosphamide plus CSFs was significantly poorer than from mice receiving cyclophosphamide alone. But, as mentioned above, hematological toxicity of the two regimens we used, and the consequent administration of CSFs, appear quite similar, and do not explain the differences in mobilization we have found. If we look in more detail at premobilization chemotherapy administered to our series of patients we find that only one out of five patients, who underwent more than two lines of cisplatinum-based chemotherapy, underwent a successful mobilization and collection; all five received VeIP. Thus Hornung and Longo's hypothesis can, at least in part, explain our results. In conclusion, in heavily pretreated patients with GCT, PBPC mobilization is feasible by a further course of salvage chemotherapy. The choice of either etoposide (VIP) or vinblastine (VeIP) can be predicated upon which of these two drugs was associated with best results during premobilization chemotherapy. In our hands, VeIP seems to be less satisfactory as a mobilizing treatment than VIP, possibly due, in some patients, to a greater number of premobilization courses of chemotherapy. High-dose cyclophosphamide, moreover, remains a good alternative for mobilizing patients refractory to salvage chemotherapy.
